Skye Bioscience, Inc. SKYE

SKYE Company Overview

Skye Bioscience, Inc. is a U.S.-based clinical-stage biotechnology company focused on the development of therapeutics targeting metabolic, inflammatory, and fibrotic diseases through modulation of the endocannabinoid system and related pathways. The company operates within the biotechnology and pharmaceutical industries, with its primary emphasis on obesity, metabolic health, and associated chronic conditions. Its core value proposition centers on developing differentiated biologic and small-molecule therapies intended to improve efficacy and tolerability compared with existing treatments in rapidly growing metabolic disease markets.

The company historically explored cannabinoid-derived pharmaceutical programs in ophthalmology and other indications before repositioning its strategy toward obesity and metabolic disorders. A major component of this transition involved advancing nimacimab, a monoclonal antibody targeting peripheral CB1 receptors, as a potential treatment for obesity and related metabolic conditions. Skye Bioscience has positioned itself within the broader metabolic therapeutics sector by pursuing non-central nervous system cannabinoid pathway modulation, which the company believes may reduce psychiatric side effects historically associated with earlier CB1-targeting drugs.